Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | YARS1 | P54577 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434143 | 1.00 | SLC7A5 (0.48) | SLC7A5YARS1MMEACECPA1 | |
| SCHEMBL9665005 | 1.00 | SLC7A5 (0.48) | SLC7A5YARS1MMEACECPA1 | |
| SCHEMBL4434130 | 1.00 | SLC7A5 (0.48) | SLC7A5YARS1MMEACECPA1 | |
| SCHEMBL9664998 | 1.00 | SLC7A5 (0.48) | SLC7A5YARS1MMEACECPA1 | |
| Hydrochloric Acid SCHEMBL20335514 | 0.99 | SLC7A5 (0.47) | SLC7A5YARS1MMEACECPA1 | |
| Hydrochloric Acid SCHEMBL924823 | 0.99 | SLC7A5 (0.47) | SLC7A5YARS1MMEACECPA1 | |
| SCHEMBL31553196 | 0.98 | YARS1 (0.46) | SLC7A5YARS1MMEOPRM1OPRD1 | |
| SCHEMBL31259944 | 0.97 | MME (0.47) | SLC7A5YARS1MMEACEOPRM1 | |
| SCHEMBL31006409 | 0.97 | MME (0.47) | SLC7A5YARS1MMEACEOPRM1 | |
| SCHEMBL38650869 | 0.97 | MME (0.47) | SLC7A5YARS1MMEACEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198647-A1 | Enhancers of Neurolysin Activity | GAP43, NLN, BDNF | SLC7A5 1148/4885YARS1 2253/4885MME 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.